Influence of coadministered antiepileptic drugs on serum zonisamide concentrations in epileptic patients: Quantitative analysis based on suitable transforming factor

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 12, 2003, Pages 1734-1738

  Fukuoka, Noriyasu ^a   Tsukamoto, Toyohisa ^a   Uno, Junji ^b   Kimura, Michio ^c   Morita, Shushi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Okehazama Hospital   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Alteration ratio; Concomitant therapy; Extracellular water volume; Level dose ratio; Transforming factor; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; TRANSFORMING GROWTH FACTOR; VALPROIC ACID; ZONISAMIDE;

ARTICLE; CALCULATION; COMPARATIVE STUDY; EPILEPSY; EXTRACELLULAR SPACE; HUMAN; MEASUREMENT; PARAMETER; QUANTITATIVE ANALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGING; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; MALE; PATIENT SELECTION; PHENYTOIN; POWDERS; REGRESSION ANALYSIS; SEX; TABLETS;

EID: 10844259016     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.1734     Document Type: Article

References (21)

1. Wilensky A. J., Friel P. N., Ojemann L. M., Dodrill C. B., McCormick K. B., Levy R. H., Epilepsia, 26, 212-220 (1985).
2. Kimura M., Tanaka N., Kimura Y., Miyake K., Kitaura T., Fukuchi H., Harada Y., Chem. Pharm Bull , 40, 193-195 (1992).
3. Ijiri Y , Ohi K , Suzuki K., Fukuoka E , Furuya T., Yoshinari S., Tamai H., Jpn. J. Hosp. Pharm., 20, 207-212 (1994).
4. Fukuoka N., Tsukamoto T , Uno J., Kimura M , Monta S., Jpn. J Hosp Pharm , 24, 652-660 (1998).
5. Fukuoka N., Tsukamoto T., Uno J., Kimura M., Morita S., Jpn J. Hosp Pharm , 26, 135-144 (2000)
6. Fukuoka N., Tsukamoto T., Uno J , Kimura M., Morita S., Jpn J Hosp Pharm., 24, 642-651 (1998).
7. Fukuoka N., Tsukamoto T., Uno J., Kimura M., Monta S., Yakugaku Zasshi, 123, 35-42 (2003).
8. Ojemann L. M., Shastri R. A., Wilensky A. J., Friel P. N., Levy R. H., Mclean J. R., Buchanan A , Ther Drug Monit., 8, 293-296 (1986).
9. Aoki S, "Tokei Program Package NAP (ver. 4 0) Manual." Igaku Shoin, Tokyo, 1995
10. Friis-Hansen B , Pediatrics, 28, 169-181 (1961)
11. Takahira H., Report of Imperial Government Institute of Nutrition, 1, 61-95 (1925).
12. Hori R., Okumura K., Kitazawa S., Koshiro A., Saitoh Y., Higuchi S., Mizugaki M., Yamaji A , Rikihisa T., Tanigawara Y., Yakuzaigaku, 49, 304-312 (1989).
13. Bartles H., Pediatr. Pharmacol., 3, 131-143 (1983).
14. Milsap R. L., Szefler S. J., "Applied Pharmacokinetics," 2nd ed., ed. by Evans W. E , Schentag J. J., Jusko W. J., Applied Therapeutics Inc., Spokan, 1986. pp 294-330.
15. Wagner J. G , Sackellares J. C., Donofrio P. D., Berent S., Sakmer E., Ther. Drug Monit., 6, 277-283 (1984).
16. Shinoda M., Akita M., Hasegawa M , Hasegawa T., Nabeshima T., Biol Pharm. Bull , 19, 1090-1092 (1996).
17. Hashimoto Y., Odani A., Tanigawara Y., Yasuhara M., Okuno T , Hon R., Biol Pharm Bull , 17, 323-326 (1994)
18. Riva R , Albani F., Contin M., Baruzzi A., Clin. Pharmacokinet., 31, 470-493 (1996)
19. Chiba K., Suganuma T., Ishizaki T., Iriki T., Shirai Y., Naitoh H., Hori M., J. Pediatr., 106, 653-658 (1985)
20. Sackellares J. C., Sato S , Dreifuss F E., Penry J. K , Epilepsia, 22, 437-441 (1981)
21. Fukuoka N., Tsukamoto T., Monta S , Jpn. J Hosp. Pharm., 23, 312-318 (1997).